Par Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Par Health is a US-based, commercial-stage pharmaceutical company specializing in generic drugs, APIs, and sterile injectables. Formed in 2019 from the merger of Mallinckrodt and Endo, it leverages a robust, vertically integrated manufacturing footprint across 10 sites in the US and India. With a portfolio of approximately 200 products and over 50 in development, the company aims to provide affordable, essential medicines globally, supported by over 4,000 employees. Its business model is centered on reliable supply, quality manufacturing, and cost-effective therapeutics.

Broad Portfolio (Multiple)

Technology Platform

Vertically integrated manufacturing and supply chain for generic drugs and APIs; TruDelivery® ready-to-use injectable systems.

Opportunities

Growing demand for affordable generics and sterile injectables, especially ready-to-use systems that improve hospital efficiency.

The company's US-based API manufacturing positions it well for supply chain reshoring initiatives and securing domestic production contracts.

Risk Factors

Faces intense price competition and margin pressure in the generic drug market.

Inherits potential legal and regulatory liabilities from its predecessor companies (Mallinckrodt and Endo).

Global manufacturing operations are subject to significant regulatory scrutiny and supply chain disruptions.

Competitive Landscape

Operates in the highly competitive global generic pharmaceutical market, competing with large players like Teva, Viatris, and Sun Pharma, as well as numerous smaller generics manufacturers. Differentiates through vertical integration, scale of US API production, and a focus on reliable supply and complex delivery forms like sterile injectables.

More companies in Small Molecule Drugs →More companies in United States →